GBT 440

• CAT Number: I001717
• CAS Number: 1446321-46-5
• Molecular Formula: C19H19N3O3
• Molecular Weight: 337.37
• Purity: 98%
• Target: HBA1
• Target Protein: P69905
• Solubility: 10 mM in DMSO
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
• InChI: InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
• InChIKey: FWCVZAQENIZVMY-UHFFFAOYSA-N
• SMILES: CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O

GBT 440（Cat No.:I001717）, also known as Voxelotor, is an oral therapy designed to treat sickle cell disease (SCD) by increasing hemoglobin’s affinity for oxygen, thereby preventing the polymerization of sickled red blood cells. By stabilizing hemoglobin in its oxygenated state, GBT 440 reduces the formation of deformed, rigid cells that cause blood flow blockages and painful vaso-occlusive crises. It helps improve overall hemoglobin levels and reduce hemolysis, offering a targeted approach to managing SCD. GBT 440 is a breakthrough therapy, improving patient outcomes and quality of life in those with sickle cell disease.

Reference

[1]. From PCT Int. Appl. (2015), WO 2015116061 A1 20150806.
[2]. From U.S. Pat. Appl. Publ. (2015), US 20150209443 A1 20150730.